Parkinson Disease

The director of the Movement Disorders Center at Baylor University Medical Center in Dallas, a part of Baylor Scott & White Health, talked about the evolution of treatment for Parkinson disease and the new promising therapies patients may seen over the coming years. [WATCH TIME: 3 minutes]

Reasons behind the CRL were not related to efficacy and do not impact Amneal’s 2023 financial guidance, which did not include IPX203 revenues.

In patients with early Parkinson disease, results showed that UB-312 was generally safe and well-tolerated, which supports the advancement of the vaccine into further clinical development.

The assistant professor of occupational therapy at the New York Institute of Technology talked about educating patients with Parkinson disease about the importance of maintaining social participation for cognitive function at ATMRD 2023. [WATCH TIME: 5 minutes]

The nurse practitioner in the movement disorder division at Georgetown University Hospital discussed differences in available therapies for movement disorders versus multiple sclerosis and using a chronic care management model in Parkinson disease. [WATCH TIME: 5 minutes]

Patients with Parkinson disease who were inpatients had significant impacts on their length of stay, readmissions, and morbidity after hospitalization when administered contraindicated medications.

At AMTRD 2023, the graduate research assistant at Brown University talked about the prevalence of rapidly progressive dementia and cognition fluctuation in Parkinson disease as well as the effects of treatments for the condition. [WATCH TIME: 5 minutes]

Robert A. Hauser, MD, MBA, director of the Parkinson’s and Movement Disorders Center at the University of South Florida, provided insight on the therapeutic potential of IPX203, and why it adds flexibility to the treatment of Parkinson disease.

At AMTRD 2023, the movement disorder neurologist at the Parkinson’s Disease and Movement Disorder Center of Silicon Valley talked about the current care landscape for Parkinson disease and improving on-time for patients experiencing OFF periods. [WATCH TIME: 5 minutes]

In a recent survey, a group of advanced practice providers recognized the importance and considered the emotional impact of the unexpected return of symptoms on the life of a patient with Parkinson disease.

Pooled results of a post hoc analysis from phase 3 studies of amantadine (Gocovri; Supernus) suggest that the therapy offers increased good ON time, and in intervals that are more predictable for patients, compared with placebo.

The companies have noted that the decision was not made because of safety or efficacy data, but to refocus efforts on the ongoing phase 2b LUMA trial of BIIB122.

The clinical professor in the department of neurology at the University of California, San Francisco, emphasized the need to restrict trichloroethylene availability and the challenges in studying environmental factors associated with Parkinson disease. [WATCH TIME: 4 minutes]

The clinical professor in the Department of Neurology at the University of California, San Francisco, talked about the association between contaminated water and Parkinson disease. [WATCH TIME: 6 minutes]

The director of the Memory & Cognitive Disorders Clinic at Hoag Neuroscience Institute provided perspective on the difficulties with testing agents for Parkinson disease psychosis, and the future outlook of treating the symptom. [WATCH TIME: 4 minutes]

Study shows that digital devices can provide objective and real-world measures of Parkinson disease, capturing key motor and nonmotor features of for early diagnosis of the neurodegenerative disorder.

The director of the James J. and Joan A. Gardner Family Center discussed data from the phase 3 BouNDless trial assessing a continuous, subcutaneous levodopa/carbidopa delivery system for patients with Parkinson disease experiencing motor fluctuations. [WATCH TIME: 3 minutes]

The director of the Memory & Cognitive Disorders Clinic at Hoag Neuroscience Institute discussed the future of treating Parkinson disease psychosis, and potential ways to lower risk of poor long-term outcomes. [WATCH TIME: 3 minutes]

A recent published study highlighted the importance of environmental risk factors for Parkinson disease, such as exposure to trichloroethylene and other volatile organic compounds.

Marcelo Bigal, MD, PhD, chief executive officer of Ventus Therapeutics, talked about the relationship between inflammation and neurodegeneration in Parkinson disease, and the importance of targeting NLRP3.

Differences in personal experience of dyskinesias in Parkinson disease were observed across multiple cultures, which could be attributable to intrinsic cultural peculiarities.

Timothy A. Leichliter, MD, a neurologist at Allegheny Health Network, provided context on the institution’s boxing program for Parkinson disease, and the need for patients to remain active.

Participants with rheumatoid arthritis had a 1.74-fold higher risk of PD compared with those without, raising importance of an elevated risk.

Jean-Cosme Dodart, PhD, senior vice president of research at Vaxxinity, discussed the progress of the UB-312 Parkinson disease vaccine, highlighting its findings from a phase 1 clinical trial, and plans for a phase 2 trial.

The CEO and cofounder of Amprion spoke about additional diagnostic uses of the αSyn seed amplification assay and its validation in the Parkinson's Progression Markers Initiative study at the 2023 AAN Annual Meeting. [WATCH TIME: 6 minutes]

Poor higher order vision at baseline was associated with worsening cognition and increased probability of death, dementia, or frailty over 3 years.

Over 48 weeks of treatment, ALXN1480 was found to be generally well-tolerated, with improvements seen in Clinical Global Impression-Improvement scores and UWDRS Parts II and III.

The medical director of the Center for Neurological Disorders at the University of Toledo discussed positive phase 3 findings assessing P2B001, and how the agent would potentially fit in the Parkinson treatment landscape. [WATCH TIME: 4 minutes]

The chief medical officer and cofounder of CND Life Sciences, who served as principal investigator of the study, offered insight into the Syn-ONe Test's clinical utility.

The pump, attached to a wearable retainer, continuously delivers the liquid medication with little to no adverse effects.